Antara Capital’s TG Therapeutics TGTX Stock Holding History

Antara Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-78,600	Closed	-$4.09M	–	129
2020 Q4	$4.09M	Buy	+78,600	New	+$2.66M	0.85%	17

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Antara Capital's TGTX Position: Q3 2022 in Review

Antara Capital sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 900,000 shares — an estimated $5.9M sold.

Antara Capital first reported a position in TGTX in Q3 2021 and held it in 3 quarters. The position peaked at $9.84M in Q1 2022. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

Antara Capital reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
Antara Capital sold 900,000 TG Therapeutics shares in Q3 2022, an estimated $5.9M.
Antara Capital first reported a position in TG Therapeutics in Q3 2021 and held it in 3 quarters.
Antara Capital's TG Therapeutics position peaked at $9.84M in Q1 2022.
183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on Antara Capital's 13F filing for Q3 2022, filed 14 Nov 2022.